Credo Technology Group Holding Ltd vs Tenet Healthcare Corporation — how do they compare? Credo Technology Group Holding Ltd trades at $217 (market cap $41.35B), while Tenet Healthcare Corporation trades at $260 (market cap $20.92B). The key difference: Credo Technology Group Holding Ltd is the larger of the two by market cap, and Tenet Healthcare Corporation is trading nearer its 52-week high, Credo Technology Group Holding Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Credo Technology Group Holding Ltd for 22 Days and Tenet Healthcare Corporation for 15 Days on average.
| CRDO | THC | |
|---|---|---|
Market Cap | $41.35B | $20.92B |
Volume | 7,290,508 | 455,764 |
Sector | Technology | Health |
52-Week High | $302.52 | $280.77 |
52-Week Low | $87.81 | $161.37 |
Typical Hold Time | 22 Days | 15 Days |
Enterprise Value | $40.61B | $32.00B |
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $220.01, down 0.37% on the day, with strong technical momentum indicated by bullish moving averages and key support at $213. The company demonstrates exceptional fundamental strength with 114.7% YoY revenue growth in Q2 2026 and a 33.83% net income margin. Recent news highlights Credo's positioning as a key beneficiary of AI infrastructure spending, with triple-digit revenue growth driven by high-speed connectivity solutions for data centers.
Outlook remains positive with 87.5% analyst buy ratings and a $267.33 consensus price target representing 21.5% upside. Key risks include premium valuation multiples (P/E 77.47) and customer concentration, while growth catalysts center on AI-driven demand and expanding optical product offerings. The stock's recent 20.3% monthly decline may present a buying opportunity given strong fundamentals.
Tenet Healthcare (THC) trades at $259.83, up 0.53% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats (Q4 2025-Q2 2026), 82.83% gross margins, and 53.31% ROE. Recent news highlights strong cash flow supporting capital returns, with Q3 2026 results expected October 29, 2026.
THC presents compelling value with a 10.04 P/E ratio and 81.25% analyst buy ratings. Upside potential to $283.36 consensus target exists, though negative cash flow trends and insider selling warrant monitoring. The stock's premium valuation (P/B 4.49) requires sustained execution amid healthcare sector volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →